C Nieder1,2, M Hintz3, O Oehlke3,4, A Bilger3,4, A L Grosu3,4. 1. Department of Oncology and Palliative Medicine, Nordland Hospital, 8092, Bodø, Norway. carsten.nieder@nlsh.no. 2. Department of Clinical Medicine, Faculty of Health Sciences, University of Tromsø, 9037, Tromsø, Norway. carsten.nieder@nlsh.no. 3. Department of Radiation Oncology, University Hospital Freiburg, 79106, Freiburg, Germany. 4. German Cancer Consortium (DKTK), Partner Site Freiburg, Freiburg, Germany.
Abstract
BACKGROUND AND PURPOSE: According to the recent TNM 8 classification, patients with metastatic non-small cell lung cancer (NSCLC) and single extrathoracic metastasis should be classified as stage M1b, while those with 2 or more metastases comprise stage M1c. The purpose of this study was to analyze the impact of this classification in patients with brain metastases. MATERIALS AND METHODS: This retrospective study included 172 patients treated with individualized approaches. Actuarial survival was calculated. Uni- and multivariate analyses were performed. RESULTS: Thirty patients (17%) were staged as M1b. Those with squamous cell cancer were more likely to harbor M1b disease (29%, adenocarcinoma 14%, other histology 17%, p = 0.16). Median survival was 5.4 months (8.0 months in case of M1b disease and 4.5 months in case of M1c disease, p = 0.001). Multivariate analysis confirmed the role of M1b stage. M1b patients managed with upfront surgery or radiosurgery had significantly longer median survival than those who received whole-brain irradiation (21.0 vs. 3.5 months, p = 0.0001) and the potential to survive beyond 5 years. CONCLUSIONS: We found the M1b classification to provide clinically relevant information. The multivariate analysis suggested that patients with M1b disease, better performance status and younger age have better survival.
BACKGROUND AND PURPOSE: According to the recent TNM 8 classification, patients with metastatic non-small cell lung cancer (NSCLC) and single extrathoracic metastasis should be classified as stage M1b, while those with 2 or more metastases comprise stage M1c. The purpose of this study was to analyze the impact of this classification in patients with brain metastases. MATERIALS AND METHODS: This retrospective study included 172 patients treated with individualized approaches. Actuarial survival was calculated. Uni- and multivariate analyses were performed. RESULTS: Thirty patients (17%) were staged as M1b. Those with squamous cell cancer were more likely to harbor M1b disease (29%, adenocarcinoma 14%, other histology 17%, p = 0.16). Median survival was 5.4 months (8.0 months in case of M1b disease and 4.5 months in case of M1c disease, p = 0.001). Multivariate analysis confirmed the role of M1b stage. M1b patients managed with upfront surgery or radiosurgery had significantly longer median survival than those who received whole-brain irradiation (21.0 vs. 3.5 months, p = 0.0001) and the potential to survive beyond 5 years. CONCLUSIONS: We found the M1b classification to provide clinically relevant information. The multivariate analysis suggested that patients with M1b disease, better performance status and younger age have better survival.
Authors: Lizza E L Hendriks; Esther G C Troost; Allan Steward; Gerben P Bootsma; Katrien De Jaeger; Ben E E M van den Borne; Anne-Marie C Dingemans Journal: Acta Oncol Date: 2014-04-23 Impact factor: 4.089
Authors: Chaosu Hu; Eric L Chang; Samuel J Hassenbusch; Pamela K Allen; Shiao Y Woo; Anita Mahajan; Ritsuko Komaki; Zhongxing Liao Journal: Cancer Date: 2006-05-01 Impact factor: 6.860
Authors: Todd W Flannery; Mohan Suntharalingam; William F Regine; Lawrence S Chin; Mark J Krasna; Michael K Shehata; Martin J Edelman; Marnie Kremer; Roy A Patchell; Young Kwok Journal: Int J Radiat Oncol Biol Phys Date: 2008-02-14 Impact factor: 7.038
Authors: Hisao Asamura; Kari Chansky; John Crowley; Peter Goldstraw; Valerie W Rusch; Johan F Vansteenkiste; Hirokazu Watanabe; Yi-Long Wu; Marcin Zielinski; David Ball; Ramon Rami-Porta Journal: J Thorac Oncol Date: 2015-12 Impact factor: 15.609
Authors: L Ceniceros; J Aristu; E Castañón; C Rolfo; J Legaspi; A Olarte; G Valtueña; M Moreno; I Gil-Bazo Journal: Clin Transl Oncol Date: 2015-08-05 Impact factor: 3.405